×
Home » Discovery Biology Pharmaceutical Services » Bioanalytical Services » Stable Cell Line (CellPower™) for Assay Development
Email to GenScript
Stable Cell Line

Stable Cell Line Services for Assay Development

Stable Cell Line

Recombinant stable cell lines are one of the widely used tools in drug discovery, toxicity testing, and basic research. Long-term stable expression of a gene of interest (GOI) is usually achieved by transfection or viral transduction of a vector containing the expression cassette of the GOI together with a selection marker (antibiotics or fluorescent proteins). In contrast to transient expression, stable cell line offers reproducible results for assay studies. Read More »

After selection, cells that have the expression cassette incorporated into the genome will be enriched, resulting in stable pool cells. By clonal selection from the stable pool cells, single clone cells are generated. Both stable pools and single clones are frequently used in research.

Recombinant stable cell line development at GenScript includes over-expression, inducible expression, and shRNA knock-down expression of GOI. In addition, we developed lentivirus based CRISPR/Cas (Lenti-CRISPR/Cas9) technologies and platforms, in order to meet the increasing need of knock out cell line engineering of GOI, in particular, difficult-to-transfect cancer cell lines.

Applications for these stable cell lines include but not limited to drug screening, gene expression regulations, functional assays, membrane protein antibody FACS screening, antibody immunization boosting, protein localization study by fusion with GFP and living cell imaging, and in vivo tumor xenograft models.

Stable Cell Line Services: Advantages working with GenScript CellPower™

Stable Cell Line Development services by CellPower™

Service Content Service Packages Deliverables Turnaround Time
Recombinant Expression(Over-Expression, Inducible Expression, Knock-Down Expression) (SC1394) Stable Pool
  • 2 vials of stable pool
  • Q-PCR & FC/western blot validations
  • over expression/inducible expression expression analysis of target gene at mRNA & protein level
  • mycoplasma-free
  • ≧90% cell viability
  • biweekly progress report
7-12 weeks
Single Clone
  • 2 single clones, 2 vials/clone (1×10^6 cells/vial)
  • Q-PCR & FC/western blot validations
  • over expression/inducible expression analysis of target gene at mRNA & protein level
  • mycoplasma-free
  • ≧90% cell viability
  • biweekly progress report
12-18 weeks
Lenti-CRISPR KO Service
(SC1652-V)
Lentiviral based for difficult-to-transfect cell lines
  • Single gene editing KO cell line
  • 1 full-allelic knock-out cell line(s) validated by sequencing
  • Cas9-stable cell pool as negative control
  • Validation of full-allelic knock-out cell lines at mRNA or protein level upon reques
  • 2 cryovials of cells per each clone, mycoplasma-free and 90% viability.
  • Biweekly update of project progress
16-26 Weeks
Service Specifications Deliverables Timeline
CellPower™ Plus Cell pool: Use new QC standard covering more than 160 species of mycoplasma
  • 2 vials of stable pool
  • Q-PCR & FC/western blot validations
  • over expression/inducible expression analysis of target  gene at mRNA & protein level
  • mycoplasma-free
  • ≧90% cell viability
  • biweekly progress report
11~13 weeks
(3 months)
Single cell clone: Use new QC standard covering more than 160 species of mycoplasma
  • 2 single clones, 2 vials/clone (1×10^6 cells/vial)
  • Q-PCR & FC/western blot validations
  • over expression/inducible expression analysis of target gene at mRNA & protein level
  • mycoplasma-free
  • ≧90% cell viability
  • biweekly progress report
15~19 weeks
(4~5months)
Pre-QC: GenScript will use the new QC standard to exclude potential mycoplasma contamination in host cells QC report 2~3 weeks
our experiences

Over-expression of GOI

our experiences   our experiences

Figure 1. PD1 expression by FACS analysis (left) and binding assay (right) in CHO-K1/PD1 cells.

Knock-down Expression of GOI

our experiences   our experiences

Figure 2. Validation of knockdown efficiency via western blotting (left) and functional assay (right).

Inducible expression of GOI

our experiences   our experiences

Figure 3. Q‐PCR (left) and western blotting (right) validation of Target A expression in HepG2 cells.

LentiCRISPR KO

our experiences
our experiences

Figure 4. Knockout of Target B in HepG2 cells validated by sequencing (above) and western blotting analysis (below).

Workflow of Our CellPower™ Stable Cell Line Development Process

Stable Cell Line Services for Assay Applications

Engineered Stable Cell Line Products

GenScript offers a wide selection of Immune Checkpoint Stable Cell Lines and GPCR Stable Cell Lines to accelerate your drug discovery. See more product introduction.

Also available are stable cell lines for protein production. See our Production Grade Stable Cell Line webpage for more details.

Quotation and Ordering

 
*
*
*
*